Endothelial cell growth factor
US5235042A · kind A · utility
Assignee
Inventor
Key dates
| Filing date | Nov 6, 1989 |
| Grant date | Aug 10, 1993 |
| Priority date | — |
| Expiry date | Nov 6, 2009 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K38/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Endothelial cell growth factor (ECG) from various sources possesses a strong and specific affinity for heparin. This strong affinity of ECG for heparin enables removal of undesired impurities from a mixture comprising ECG by: a) contacting immobilized heparin with the mixture to form a heparin-ECG complex; b) separating uncomplexed mixture from the complex; and c) contacting the complex with a salt solution of a salt concentration and pH effective to separate the ECG from the heparin. The resulting purified ECG (or fragment thereof) is useful in therapeutics and as an additive for cell culturing. The purified ECG is also useful to raise antibodies that are used in therapeutics and in ECG immunoassays.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.